The Marc Ladanyi Lab

Ladanyi lab

The research program in this laboratory focuses on the genomics and molecular pathogenesis of sarcomas and thoracic malignancies, with an emphasis on clinical translation of potential diagnostic markers and therapeutic targets. Dr. Ladanyi also co-directs (with Chris Sander) the Genome Data Analysis Center at Memorial Sloan Kettering, which is part of the TCGA project network.

Examples of recent contributions include the validation of DUSP4 as a driver gene for 8p losses in EGFR-mutant lung adenocarcinomas, the establishment of methods for enhanced detection of the EGFR T790M secondary mutation in the setting of acquired resistance to EGFR inhibitors, the discovery of BAP1 mutations in mesotheliomas with 3p losses, the identification of novel, recurrent HEY1-NCOA2 and KIF5B-RET fusions in mesenchymal chondrosarcoma and lung adenocarcinoma, respectively, both based on mining of exon-level expression data, as well as major involvement in the TCGA Network marker papers on the genomics of glioblastoma, ovarian carcinoma, and squamous lung cancer. Ongoing projects are addressing further questions in lung adenocarcinoma, mesothelioma, and several sarcoma types using whole exome and whole transcriptome sequencing, ChIP-seq, Sequenom mass spectrometry genotyping, NanoString expression profiling, RNAi screens, chemical screens, and proteomic approaches.

Pictured: Marc Ladanyi

Marc Ladanyi, MD

Professor

Research Focus

Molecular pathologist Marc Ladanyi studies the molecular pathogenesis of sarcomas, lung cancer, and mesothelioma.

Education

MD, McGill University